Shares of Acer Therapeutics Inc (NASDAQ:ACER) have earned an average recommendation of “Hold” from the nine analysts that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $22.33.
Several research firms have recently weighed in on ACER. Zacks Investment Research raised shares of HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a report on Friday, May 17th. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. BidaskClub raised shares of YRC Worldwide from a “hold” rating to a “buy” rating in a report on Saturday, April 13th. Needham & Company LLC cut shares of Acer Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Roth Capital reduced their target price on shares of Acer Therapeutics from $66.00 to $9.00 in a report on Tuesday, June 25th.
A number of hedge funds have recently made changes to their positions in ACER. SG Americas Securities LLC bought a new stake in shares of Acer Therapeutics in the 1st quarter worth approximately $101,000. Laurion Capital Management LP bought a new stake in shares of Acer Therapeutics in the 1st quarter worth approximately $253,000. Tibra Equities Europe Ltd bought a new stake in shares of Acer Therapeutics in the 1st quarter worth approximately $297,000. Barclays PLC bought a new stake in shares of Acer Therapeutics in the 4th quarter worth approximately $499,000. Finally, Northern Trust Corp lifted its position in shares of Acer Therapeutics by 5.7% in the 4th quarter. Northern Trust Corp now owns 33,572 shares of the biopharmaceutical company’s stock worth $676,000 after acquiring an additional 1,797 shares during the period. 31.11% of the stock is owned by institutional investors and hedge funds.
Acer Therapeutics (NASDAQ:ACER) last released its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.04. On average, sell-side analysts predict that Acer Therapeutics will post -2.92 earnings per share for the current year.
About Acer Therapeutics
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders.
Further Reading: How are dividend achievers different from dividend aristocrats?
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.